Kathleen Elias

Kathleen Elias

Company: Seal Rock Therapeutics

Job title: Vice President Research and Translational Medicine


Investigating Combinational Approaches to Elevate GLP-1 Therapies: Role of 2nd generation ASK1 inhibitor SRT-015 treatment for MASH fibrosis 1:50 pm

SRT-015 is an oral compound with direct pleotropic effects on the liver including fibrotic, inflammatory and apoptosis inhibition for possible use in all MASH fibrosis stages Combination therapy with GLP-1s and other metabolic agents In a phase 1 clinical trial, SRT-015 demonstrated pharmacokinetics that enables daily dosing with a favorable safety profileRead more

day: Conf Day 1 Track 2 PM

Panel | Translating GLP-1s, Rezmiteron, FGF21 Therapies into Clinical Practice Guidelines in a Rapidly Changing Landscape 3:30 pm

Assessing how current therapies fit into the standard of care Navigating the future of combination therapies to optimize treatment Evaluating how this will play out in the real world with access, non-responders, standard of care and the shift to primary care providersRead more

day: Conf Day 1 EOD

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.